← Back to Search

Monoclonal Antibodies

LY3502970 Pharmacokinetics in Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 16 days postdose
Awards & highlights

Study Summary

This trial tests how a drug is broken down and cleared by the body. Participants will take the drug for 9 weeks.

Who is the study for?
This trial is for healthy adults with a body weight of at least 45 kg and a BMI between 18.5 to 35.0 kg/m². Participants must not use drugs of abuse, have allergies to LY3502970 or its components, and women must not be able to bear children or be lactating.Check my eligibility
What is being tested?
The study tests how LY3502970 and its radioactive version are absorbed, broken down, and eliminated by the body. It involves monitoring participants for up to approximately 9 weeks.See study design
What are the potential side effects?
Since this is an early-phase study primarily focused on pharmacokinetics (how the drug moves through the body), specific side effects are not listed but will be monitored throughout the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 16 days postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 16 days postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pharmacokinetics (PK): Absolute bioavailability of LY3502970
Secondary outcome measures
PK: AUC [0-∞] of LY3502970
PK: AUC [0-∞] of [14C]-LY3502970
PK: Area Under the Curve Concentration Versus Time Curve From zero to Infinity (AUC [0-∞]) of Total Radioactivity
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: LY3502970 + [14C]-LY3502970Experimental Treatment2 Interventions
Single dose of LY3502970 administered orally followed by single dose of [¹⁴C]-LY3502970 administered intravenously (IV)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[14C]-LY3502970
2023
Completed Phase 1
~10
LY3502970
2021
Completed Phase 2
~1220

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,615 Previous Clinical Trials
3,201,048 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,344 Previous Clinical Trials
405,242 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants who are younger than 80 years of age qualified to join the experiment?

"The parameters of this clinical investigation require that patients are between 21 and 70 years old. For those outside of this age range, there are 66 trials for minors younger than 18 and 399 studies available to individuals over 65."

Answered by AI

Who is the ideal candidate for this research endeavor?

"To qualify for this research, candidates must possess a healthy stature and be aged between 21 and 70. The clinical trial is currently selecting 10 participants."

Answered by AI

How hazardous is the combination of LY3502970 and [14C]-LY3502970 to human health?

"The safety of the combination drug LY3502970 + [14C]-LY3502970 was assessed as a 1 due to its Phase 1 status indicating limited evidence for efficacy and safety."

Answered by AI

Are there currently vacancies in this research protocol for participants?

"According to details on clinicaltrials.gov, this trial is no longer enrolling participants; the initial posting was made October 19th 2023 and the last update occurred 10 days prior. Fortunately, 825 other medical studies are still recruiting volunteers at present."

Answered by AI

Who else is applying?

What site did they apply to?
Covance Clinical Research Inc
What portion of applicants met pre-screening criteria?
Met criteria

Why did patients apply to this trial?

Interested in the process and compensation.
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
A Phase I Study of LY3502970 in Healthy Participants
2023. "A Phase I Study of LY3502970 in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06085482.
All > Madison
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top